EN
Home/Canada/Blog/Why doesn’t any province cover Wegovy or Zepbound for weight loss?
CACanada Coverage and insurance

Why doesn’t any province cover Wegovy or Zepbound for weight loss?

How a weight-loss medicine gets onto a public drug plan, what Canada’s Drug Agency and Quebec’s INESSS decided about Wegovy, and why the price talks ended.

GLP Guidebook teamPublished 12 Oct 20268 min read16 sourcesWritten from published sources

Written for Canada, from Canadian sources.

The short answer

Because the national review and the price talks never met. In July 2025, Canada’s Drug Agency said plans could fund Wegovy only for people with heart disease, and only with a price cut; its model needed 67% off. Talks ended without a deal on 1 December 2025. We found no public plan listing Zepbound, as of 12 October 2026.

Key takeaways

  • No public drug plan we checked covers Wegovy or Zepbound for weight management, as of 12 October 2026.1,2
  • Canada’s Drug Agency recommended funding Wegovy in July 2025 only for adults with a BMI of 27 or more and established heart disease, and only with a price reduction (its model needed 67% off).3
  • The pan-Canadian price talks ended without agreement on 1 December 2025, after Novo Nordisk said it would no longer seek public coverage of Wegovy.1
  • Quebec’s Health Minister decided on 4 March 2026 not to list Wegovy for people with a BMI of 35 or more.4
  • BC said it will review generic semaglutide for all approved uses once generics reach the market.1
Before you go further
  • GLP‑1 medicines are prescription drugs in Canada. Nothing here is a reason to start, stop or switch one.5
  • We name brands and official prices as facts. We don’t recommend, rank or link to any brand, pharmacy, clinic or program.
  • For weight management, Health Canada has approved Wegovy, Zepbound and Saxenda, and the generic Sevmia. Ozempic and Mounjaro are approved for type 2 diabetes.6,5
  • Trial results are averages. Some people lose much less, and every benefit comes with risks: see our side effects guide.
On this page
  1. How does a medicine get onto a public drug plan?
  2. What did Canada’s Drug Agency recommend for Wegovy?
  3. What happened in the price talks?
  4. What did Quebec decide?
  5. What about Zepbound?
  6. Could this change?
  7. Questions people ask
  8. How we researched this
  9. Sources

How does a medicine get onto a public drug plan?

Health Canada approves it, Canada’s Drug Agency recommends whether to fund it (INESSS in Quebec), the provinces negotiate a price, and each plan decides.1,4

Approval and funding are separate questions. Health Canada decides whether a medicine is safe and works. Canada’s Drug Agency (CDA-AMC) then judges whether it is good value for public plans.1

The pan-Canadian Pharmaceutical Alliance (pCPA) negotiates the price for the provinces. BC’s own Drug Benefit Council then weighs the agency’s review, patient input and budget impact.1 Quebec runs its own review body, INESSS, and the Health Minister decides.4

What did Canada’s Drug Agency recommend for Wegovy?

In July 2025 it backed funding only for adults with established heart disease and a BMI of 27 or more, and only with a price reduction.3

Its wording was “reimburse with conditions”. Established heart disease meant a prior heart attack, a prior stroke, or symptomatic peripheral artery disease (narrowed arteries in the legs).3 That replaced a 2022 recommendation against funding Wegovy at all.3

The conditions: a first approval of up to a year, then renewal only with at least a 5% drop in BMI or body weight, checked yearly.3 At list price, the agency put Wegovy at $5,066 per patient per year.7

The evidence came from the SELECT trial. BC’s summary says Wegovy reduced major heart complications against a dummy injection in this group, with “no benefits demonstrated regarding CV death”.1 The agency said it could not draw conclusions for people without heart disease.3

RisksThe risks, in brief
  • Stomach effects. About 44 in 100 people on Wegovy 2.4 mg felt sick (nausea), against 16 in 100 on a dummy injection. On Zepbound 15 mg it was about 28 in 100, against about 9 in 100.8,9
  • Gallbladder. Gallstones affected about 16 in 1,000 people on Wegovy, against 7 in 1,000 on a dummy injection. An inflamed gallbladder affected about 6 in 1,000 on Zepbound, against 2 in 1,000.8,9
  • Pancreatitis (an inflamed pancreas): severe stomach pain that won’t go away, sometimes spreading to the back.8
  • Dehydration from vomiting or diarrhea can harm the kidneys.8
  • Thyroid and pregnancy. Not for anyone with a personal or family history of medullary thyroid cancer, or MEN 2. Canada’s obesity guideline advises against these medicines in pregnancy, while breastfeeding or when trying to conceive.9,6
Full detail in our side effects guide →
Get help now: call 911 or go to the nearest emergency department for severe stomach pain that won’t go away, with or without vomiting. It can be pancreatitis. Not sure? Call 811 to speak to a nurse in most provinces (Info-Santé 811 in Quebec).8,10

What happened in the price talks?

Novo Nordisk told the pCPA it would no longer seek public coverage of Wegovy, and the talks ended without agreement on 1 December 2025.1

BC then listed Wegovy as a “Non-benefit” on 18 December 2025. Its reasons: Wegovy “does not represent good value” at the list price, and there is uncertainty about long-term weight loss and heart benefit.1

A 67% price cut is what the agency’s model needed for Wegovy to meet its cost-effectiveness threshold, and the maker declined to negotiate.3,1 Novo Nordisk’s Ozempic, approved for diabetes, stayed on the plans.11,12

Free toolWork out a 6- or 12-month cost

Pick a medicine and a dose plan, then add what your plan pays. No sign-up.

Open the calculator

What did Quebec decide?

INESSS recommended against listing Wegovy for heart-risk reduction and for people with a BMI of 35 or more. The Minister refused the second and postponed the first.13,4

For cardiovascular prevention, INESSS’s recommendation was “Refusal of registration – All aspects”. The Minister suspended the decision on 11 December 2025.13

For improving heart and metabolic measures in people with a BMI of 35 or more, INESSS refused on therapeutic value. On 4 March 2026, the Minister decided not to list it.4

What about Zepbound?

Zepbound was first authorized in Canada on 13 May 2025. We found no public plan that lists it, or any tirzepatide product.14,2

Ontario’s formulary has no tirzepatide row at all.2 Quebec lists Mounjaro, the diabetes brand of the same medicine, as private insurance only.15 We found no public review decision on Zepbound for weight.

Canada’s obesity guideline still recommends medicines like semaglutide 2.4 mg and tirzepatide for adults with a BMI of 30 or more, or 27 or more with weight-related health problems.6 A guideline describes options; a plan decides what it pays for.

Could this change?

Possibly. BC said it will review generic semaglutide “for all approved indications” when generics are on the market, and a generic Wegovy has been approved.1,16

Sevmia, Apotex’s generic of Wegovy, was approved on 29 June 2026. It was not yet marketed on 12 October 2026.5 Ontario’s formulary lists Sevmia at $325.05 a pen, but as “off-formulary”, so not a benefit.2

Until a plan lists one, people pay through private insurance or themselves. See private insurance and GLP‑1s and what Sevmia is.

Questions people ask

Is Wegovy covered by any province?

No public plan we checked covers Wegovy for weight management, as of 12 October 2026. BC lists it as a non-benefit.1

Why did CDA-AMC only recommend Wegovy for heart patients?

The SELECT trial showed fewer major heart complications in people with established heart disease. The agency said it could not draw conclusions for people without heart disease.3,1

What is the pCPA?

The pan-Canadian Pharmaceutical Alliance negotiates drug prices for public plans. Its Wegovy talks ended without agreement on 1 December 2025.1

Does RAMQ cover Wegovy?

No. Quebec’s Minister decided on 4 March 2026 not to list Wegovy for people with a BMI of 35 or more, and postponed the decision on heart-risk reduction.4,13

Will generic Wegovy be covered?

Not yet. BC said it will review generic semaglutide for all approved uses once generics are marketed. Sevmia was approved but not marketed on 12 October 2026.1,5

How we researched this

We read the decision documents themselves: Canada’s Drug Agency’s July 2025 recommendation and economic review, BC PharmaCare’s December 2025 decision, and INESSS’s notices to the Minister. Ontario’s formulary was checked on 12 October 2026.

We found no public statement from the pCPA itself, so the talks’ outcome comes from BC’s decision document.

Before you move on

  • Check whether you have private drug coverage through work or school.
  • Ask your plan whether it covers weight management at all.
  • Ask your prescriber whether you meet any plan’s criteria.
  • Look out for decisions on generic semaglutide.
  • Budget for a year, not a month.
Cost calculatorYour optionsCould it be an option?

More from the Canada blog

CACanadaDoes private insurance cover Ozempic, Wegovy or Zepbound in Canada?CACanadaWhat is Sevmia, the generic Wegovy, and when will it be available?CACanadaDoes your province cover Ozempic? Ontario, BC, Alberta, Quebec and others compared
About GLP Guidebook

The monthly Canada update

An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: Health Canada approvals, recalls, provincial coverage changes and official prices. How we write

Was this post easy to understand?

Sources

  1. BC PharmaCare. Drug coverage decision: semaglutide (Wegovy), “Non-benefit”, 18 December 2025 (pCPA negotiations concluded without agreement on 1 December 2025; Novo Nordisk no longer seeking public coverage; generic semaglutide to be reviewed). PDF
  2. Ontario Ministry of Health. Ontario Drug Benefit Formulary search, semaglutide rows (Ozempic $227.94 per pen with $78.141 paid; Apo-Semaglutide and Dr. Reddy’s $78.141; Sevmia $325.048, off-formulary interchangeable; Wegovy off-formulary interchangeable, no price; Rybelsus $7.5303 per tablet; no tirzepatide row). Checked 12 October 2026. Link
  3. Canada’s Drug Agency (CDA-AMC). Semaglutide (Wegovy) reimbursement recommendation SR0841, July 2025 (“Reimburse with conditions” for adults with BMI 27 or more and established cardiovascular disease; renewal at 5% loss; 67% price reduction; earlier 2022 recommendation against). Link
  4. INESSS. Wegovy, amélioration des paramètres cardiométaboliques (IMC ≥ 35 kg/m²): extract of notice to the Minister (refusal on therapeutic value; Minister’s decision not to list, 4 March 2026). Link
  5. Health Canada. Drug Product Database: status records for every semaglutide product (Ozempic, Rybelsus, Wegovy, Plosbrio, Poviztra; generics from Dr. Reddy’s, Apotex, Aspen and Sandoz, and Sevmia). Searched 12 October 2026. Link
  6. Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Canadian Adult Obesity Clinical Practice Guideline: Pharmacotherapy for Obesity Management in Adults, 2025 update. Obesity Canada, Version 3, 11 August 2025 (recommendations 1–13; six medicines approved for obesity; off-label use discouraged; pregnancy). PDF
  7. Canada’s Drug Agency (CDA-AMC). Semaglutide (Wegovy) SR0841 clinical and pharmacoeconomic review (“The unit cost is $388.64 per pen (or $97.16 per dose)”; annual cost $5,066; Ozempic $2,844 to $5,688 a year). 2025. Link
  8. Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, date of authorization 2 October 2026 (indications; dose escalation; STEP 1–3 results and adverse reactions; pancreatitis, gallbladder, kidney and pregnancy warnings; storage). PDF
  9. Eli Lilly Canada. Zepbound (tirzepatide injection) Product Monograph, date of authorization 11 June 2026 (indications; “The ZEPBOUND multi-dose KwikPen contains 4 doses”; doses; SURMOUNT-1 and -2 results and adverse reactions; coadministration with Mounjaro not recommended; contraindications). PDF
  10. Heart and Stroke Foundation of Canada. Medical services by phone (811 in most provinces and Yukon; Info-Santé 811 in Quebec; other numbers in Manitoba, the Northwest Territories and Nunavut). Checked 12 October 2026. Link
  11. Ontario Ministry of Health. Executive Officer notice: Ozempic listed with Limited Use codes 665–667 (for adults with type 2 diabetes when control is not achieved on the maximum tolerated dose of metformin, or metformin is contraindicated or inappropriate; authorization period indefinite). 26 January 2024. PDF
  12. BC PharmaCare. Limited coverage drugs: semaglutide (Special Authority after inadequate control on maximum tolerated metformin; approval indefinite; up to 1 mg weekly; 2 mg under review). Updated 21 April 2026. Link
  13. INESSS. Wegovy, prévention cardiovasculaire: extract of notice to the Minister (“Refusal of registration – All aspects”; Minister’s decision suspended, 11 December 2025). Link
  14. Eli Lilly Canada. Health Canada approves Zepbound for obstructive sleep apnea (Zepbound first authorized 13 May 2025). Press release, 16 June 2026. Link
  15. Diabète Québec. Table of diabetes medications and their coverage (RAMQ exception-drug criteria for Ozempic; Mounjaro private insurance only, not on the RAMQ list; NIHB Limited Use). March 2026. PDF
  16. Apotex. Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management. Press release, 30 June 2026. Link

Last checked 12 Oct 2026 · Next review due 12 Apr 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your family doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write